Privately-held Charleston Laboratories Inc.’s resubmitted new drug application for its novel investigational treatment, CL-108, with the proposed trade name HYDEXOR, is all set to be reviewed by an FDA panel on February 14, 2018.Charleston Laboratories and Daiichi Sankyo Inc. have a strategic collaboration for the development and marketing of CL-108.The companies are seeking approval of CL-108 for the relief of moderate to severe acute pain while preventing and reducing opioid-induced nausea and vomiting (OINV) for patients with pain severe enough to require an opioid.The FDA had declined to approve CL-108 last February.